Late-breaking trial results for obefazimod show significant efficacy, positioning the first-in-class oral therapy in a competitive market.
Shares fall despite strong Q3 sales, as expiring EV tax credits and valuation concerns spook investors.
Combination therapy approval for small cell lung cancer offers a new standard of care and a bullish signal for the pharmaceutical sector.
The utility giant reaffirmed its adjusted EPS targets for 2025 and 2026, reinforcing a long-term earnings growth strategy of 7% to 9% through 2029.
A coalition of influential investors is urging shareholders to reject the CEO's new compensation package, citing major governance concerns.
First-of-its-kind maintenance therapy approved for extensive-stage small cell lung cancer, a historically difficult-to-treat malignancy.
H.C. Wainwright more than doubles its price target to $7 as the company delivers its first electrolyzer to a major green hydrogen facility in Portugal.
The designation for ALTO-101 targets cognitive impairment, a debilitating aspect of schizophrenia with no currently approved treatments.